Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
2001 1
2004 2
2007 1
2008 1
2009 1
2010 1
2011 4
2012 2
2013 1
2014 3
2016 5
2017 4
2018 5
2019 4
2020 3
2021 5
2022 7
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
Fa'ak F, Buni M, Falohun A, Lu H, Song J, Johnson DH, Zobniw CM, Trinh VA, Awiwi MO, Tahon NH, Elsayes KM, Ludford K, Montazari EJ, Chernis J, Dimitrova M, Sandigursky S, Sparks JA, Abu-Shawer O, Rahma O, Thanarajasingam U, Zeman AM, Talukder R, Singh N, Chung SH, Grivas P, Daher M, Abudayyeh A, Osman I, Weber J, Tayar JH, Suarez-Almazor ME, Abdel-Wahab N, Diab A. Fa'ak F, et al. Among authors: talukder r. J Immunother Cancer. 2023 Jun;11(6):e006814. doi: 10.1136/jitc-2023-006814. J Immunother Cancer. 2023. PMID: 37328287 Free PMC article.
Guillian-Barre syndrome.
Talukder RK, Sutradhar SR, Rahman KM, Uddin MJ, Akhter H. Talukder RK, et al. Mymensingh Med J. 2011 Oct;20(4):748-56. Mymensingh Med J. 2011. PMID: 22081202 Review.
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Koshkin VS, et al. Among authors: talukder r. Cancer. 2022 Mar 15;128(6):1194-1205. doi: 10.1002/cncr.34057. Epub 2021 Dec 9. Cancer. 2022. PMID: 34882781 Free article.
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
Bakaloudi DR, Talukder R, Lin GI, Makrakis D, Diamantopoulos LN, Tripathi N, Agarwal N, Zakopoulou R, Bamias A, Brown JR, Pinato DJ, Korolewicz J, Jindal T, Koshkin VS, Murgić J, Miletić M, Frobe A, Johnson J, Zakharia Y, Drakaki A, Rodriguez-Vida A, Rey-Cárdenas M, Castellano D, Buznego LA, Duran I, Carballeira CC, Barrera RM, Marmorejo D, McKay RR, Stewart T, Gupta S, Ruplin AT, Yu EY, Khaki AR, Grivas P. Bakaloudi DR, et al. Among authors: talukder r. Clin Genitourin Cancer. 2023 Oct;21(5):584-593. doi: 10.1016/j.clgc.2023.06.008. Epub 2023 Jun 20. Clin Genitourin Cancer. 2023. PMID: 37414620
Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Makrakis D, Bakaloudi DR, Talukder R, Lin GI, Diamantopoulos LN, Jindal T, Vather-Wu N, Zakharia Y, Tripathi N, Agarwal N, Dawsey S, Gupta S, Lu E, Drakaki A, Liu S, Zakopoulou R, Bamias A, Fulgenzi CM, Cortellini A, Pinato D, Barata P, Grivas P, Khaki AR, Koshkin VS. Makrakis D, et al. Among authors: talukder r. Clin Genitourin Cancer. 2023 Apr;21(2):286-294. doi: 10.1016/j.clgc.2022.11.003. Epub 2022 Nov 13. Clin Genitourin Cancer. 2023. PMID: 36481176 Free article.
Gastroretentive delivery systems: a mini review.
Talukder R, Fassihi R. Talukder R, et al. Drug Dev Ind Pharm. 2004;30(10):1019-28. doi: 10.1081/ddc-200040239. Drug Dev Ind Pharm. 2004. PMID: 15595568 Review.
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR. Talukder R, et al. Clin Genitourin Cancer. 2022 Dec;20(6):558-567. doi: 10.1016/j.clgc.2022.08.006. Epub 2022 Aug 19. Clin Genitourin Cancer. 2022. PMID: 36155169 Free PMC article.
Financial and functionality analysis of a biogas plant in Bangladesh.
Bedana D, Kamruzzaman M, Rana MJ, Mustafi BAA, Talukder RK. Bedana D, et al. Among authors: talukder rk. Heliyon. 2022 Sep 20;8(9):e10727. doi: 10.1016/j.heliyon.2022.e10727. eCollection 2022 Sep. Heliyon. 2022. PMID: 36185129 Free PMC article.
52 results